ライフサイエンスコーパス: drug susceptibility test

1 detection of R5 and X4 HIV-1 replication and drug susceptibility tests.

2 mprovement of turnaround time for phenotypic drug susceptibility testing.

3 nce was obtained and the results of in vitro drug susceptibility testing.

4 chelonae that were originally submitted for drug susceptibility testing.

5 losis identification, and from 55 to 75% for drug susceptibility testing.

6 sed recombination followed by sequencing and drug susceptibility testing.

7 a multifunctional assay for TB diagnosis and drug susceptibility testing.

8 owth Indicator Tube (MGIT) culture with MGIT drug susceptibility testing.

9 must be accelerated along with comprehensive drug susceptibility testing.

10 rapid diagnosis, therapeutic monitoring, and drug susceptibility testing.

11 eatment rely on access to rapid and reliable drug-susceptibility testing.

12 rowth indicator tube (MGIT) culture,and MGIT drug-susceptibility testing.

13 rogram (MPEP) for Mycobacterium tuberculosis Drug Susceptibility Testing, 1994 to 2008, implemented b

14 .49) as were those who did not have baseline drug-susceptibility tests (2.24; 1.31-3.83).

15 erculosis (59%); and radiometric methods for drug susceptibility testing (55%).

16 Among 4826 (93.5%) with drug susceptibility testing, 82 (1.7%) had MDR-TB.

17 00%, respectively, compared to those of MGIT drug susceptibility testing, after the exclusion of syno

18 In drug susceptibility testing, all isolates of M. abscessu

19 predict treatment response than traditional drug susceptibility testing and open avenues for persona

20 with modifiable risk factors such as lack of drug susceptibility testing and suboptimal initial antit

21 mear-positive tuberculosis were subjected to drug susceptibility testing and to spoligotyping and var

22 correlating molecular data with results from drug susceptibility testing and, optimally, associated p

23 R) tuberculosis were evaluated by phenotypic drug-susceptibility testing and mutation detection metho

24 However, further interventions, such as drug-susceptibility testing and standardised or individu

25 nd analyzed using smear microscopy, culture, drug susceptibility testing, and NAAT.

26 ltidrug-resistant tuberculosis, low rates of drug susceptibility testing, and poor access to antiretr

27 bacterial cultures, molecular and phenotypic drug susceptibility tests, and radiographic studies, amo

28 l growth indicator tube (MGIT) culture, MGIT drug-susceptibility testing, and the Xpert MTB/RIF assay

29 Laboratory facilities for drug susceptibility testing are inadequate in most tuber

30 To assess the value of phenotypic drug susceptibility testing as a predictor of antiretrov

31 specimen was compared with culture tests and drug susceptibility testing as reference standards.

32 We also used cultures, drug-susceptibility testing, bacterial genotyping, and m

33 These patients were referred for culture and drug susceptibility testing because of the clinical susp

34 d be useful for many applications, including drug susceptibility testing, but current technologies ha

35 Chest radiography and sputum culture drug susceptibility testing can assist physicians in pre

36 Drug susceptibility testing demonstrated a multidrug-res

37 CR are cultured, owing to higher-sensitivity drug susceptibility testing, differential diagnosis, and

38 -2238M USD for a tuberculosis detection plus drug susceptibility test (DST) all-in-one or 1.5M tests/

39 ease treated with regimens tailored to their drug susceptibility test (DST) result or to the DST resu

40 lected cases for which the initial and final drug susceptibility test (DST) results had been reported

41 ure results with available initial and final drug susceptibility test (DST) results.

42 culosis (MDR-TB) in comparison with standard drug susceptibility testing (DST) and compared the resul

43 rug regimens are creating new priorities for drug susceptibility testing (DST) and surveillance.

44 site reference standard that used phenotypic drug susceptibility testing (DST) and targeted sequencin

45 The Genotype MTBDRplus(R), a rapid drug susceptibility testing (DST) assay used to detect r

46 g active tuberculosis (TB) and lack of rapid drug susceptibility testing (DST) at the point of care r

47 ltaneously, CDC does growth-based phenotypic drug susceptibility testing (DST) by the indirect agar p

48 icenter study was carried out to evaluate if drug susceptibility testing (DST) can be successfully ca

49 R alone for selected genotypic technologies) drug susceptibility testing (DST) followed, if necessary

50 tuberculosis depends upon reliable and valid drug susceptibility testing (DST) for pyrazinamide, etha

51 Expanding access to culture and drug susceptibility testing (DST) for TB diagnosis may h

52 Conventional culture-based drug susceptibility testing (DST) for the second-line an

53 Noted issues with PZA Drug Susceptibility Testing (DST) have driven the search

54 Culture-based drug susceptibility testing (DST) may take 4 weeks or lo

55 of this study was to establish standardized drug susceptibility testing (DST) methodologies and refe

56 tested using conventional liquid culture and drug susceptibility testing (DST) on solid medium and 10

57 hs, which is currently needed for phenotypic drug susceptibility testing (DST) results.

58 ginal benefit for regimens based directly on drug susceptibility testing (DST) results.

59 Mycobacterium tuberculosis using phenotypic drug susceptibility testing (DST) to determine the exten

60 e isolates underwent standardized phenotypic drug susceptibility testing (DST) to isoniazid (INH), ri

61 However, the most appropriate use of drug susceptibility testing (DST) to support this regime

62 nal methods including AFB smear, culture and drug susceptibility testing (DST) using both an absolute

63 PZA drug susceptibility testing (DST) was performed directly

64 pecies level, concordance with culture-based drug susceptibility testing (DST), and turnaround time.

65 update and clarify policies on tuberculosis drug susceptibility testing (DST), the World Health Orga

66 diagnosis (sensitivity, 65.4%) and reliable drug susceptibility testing (DST).

67 erformance of the test to that of phenotypic drug susceptibility testing (DST).

68 rains based on the agar proportion method of drug susceptibility testing (DST).

69 ed 5-drug regimen while awaiting second-line drug-susceptibility test (DST) results.

70 A target product profile for a molecular drug-susceptibility test (DST) was developed on the basi

71 encing (WGS) has the potential to accelerate drug-susceptibility testing (DST) to design appropriate

72 t followed by confirmatory test (TT), and 4) drug-susceptibility testing (DST).

73 of mycobacterial species, and culture-based drug-susceptibility testing (DST).

74 have phenotypic heterogeneity in results of drug-susceptibility tests (DSTs).

75 Most of the new drug susceptibility tests endorsed by the World Health O

76 Drug susceptibility testing established that ald loss of

77 rs a rapid, accurate, 1- to 3-day phenotypic drug susceptibility test for first- and second-line drug

78 eful as a rapid 3-day first- and second-line drug susceptibility test for M. tuberculosis.

79 by community health workers; and (4) a rapid drug susceptibility test for use at the microscopy cente

80 Improved diagnostics and drug susceptibility testing for Mycobacterium tuberculos

81 ed culture-positive MTBC cases with reported drug susceptibility tests for PZA in 38 jurisdictions ro

82 TB burden setting suggested that a new rapid drug-susceptibility test for TB may be more practical fo

83 hese characterisations to predict phenotypic drug-susceptibility testing for an independent validatio

84 Drug-susceptibility testing for study purposes was done

85 and the proportion using BACTEC for primary drug susceptibility testing has increased from 26.2 to 7

86 Limited availability of drug susceptibility testing, high costs and inefficienci

87 growth characteristics with biochemical and drug susceptibility tests; (ii). molecular techniques in

88 ion study for the introduction of this rapid drug susceptibility test in Kinshasa, Democratic Republi

89 by construction of cloned viral mutants and drug susceptibility testing in cell culture.

90 ould be accompanied by increased support for drug susceptibility testing in developing countries to b

91 sistant tuberculosis with sputum culture and drug susceptibility testing in patients with known or su

92 ons were not different than culture-based FQ drug susceptibility testing in predicting the hazard of

93 boratory systems through increased access to drug-susceptibility testing in Uganda.

94 nce was compared to gold-standard phenotypic drug susceptibility tests, including Lowenstein-Jensen (

95 Human immunodeficiency virus type 1 (HIV-1) drug susceptibility testing is often curtailed because s

96 rug susceptibility testing, yet conventional drug susceptibility testing is slow, and molecular testi

97 Phenotypic drug-susceptibility testing is slow and expensive, and c

98 to the cumbersome nature of the conventional drug susceptibility testing method using mouse footpad i

99 st below the resolving capability of current drug susceptibility testing methodologies, and may expla

100 Molecular drug susceptibility testing methods provide considerable

101 nce to AMK and KAN in all three conventional drug susceptibility testing methods.

102 For isoniazid and rifampin drug susceptibility testing, MODS is as accurate as and

103 eference MIC quality control (QC) ranges for drug susceptibility testing of antimycobacterials, inclu

104 riptase sequencing, protease sequencing, and drug susceptibility testing of HIV-1.

105 own to be useful for the rapid detection and drug susceptibility testing of Mycobacterium tuberculosi

106 ted growth and detection of mycobacteria and drug susceptibility testing of Mycobacterium tuberculosi

107 Conventional indirect drug susceptibility testing of Mycobacterium tuberculosi

108 fection treatment-tailored to the results of drug susceptibility testing of the putative source case-

109 Drug susceptibility tests of recombinant patient isolate

110 We performed whole genome sequencing and drug susceptibility testing on 337 clinical isolates of

111 of viable M. paratuberculosis cells, such as drug susceptibility testing or environmental survival st

112 The drug susceptibility testing performance of a broth-based

113 amikacin, kanamycin, or capreomycin based on drug susceptibility test results from initial and follow

114 Disease Control and Prevention in 1993 added drug susceptibility test results to the information coll

115 More than 50% of secondary cases with drug susceptibility test results were concordant with th

116 with crude risks varying greatly by initial drug susceptibility test results: 1 in 1909 if initially

117 The rate of reproducibility of the drug susceptibility testing results between the particip

118 specificity of 100% relative to conventional drug susceptibility testing results for RIF resistance.

119 ype patterns of M. tuberculosis strains with drug-susceptibility test results and epidemiologic infor

120 d the proportion of household contacts whose drug-susceptibility test results matched those of the pu

121 were 1800 patients with culture-positive TB, drug-susceptibility test results, and genotyping results

122 cterial isolates that may dictate to conduct drug susceptibility test routinely.

123 Drug susceptibility tests showed that biological clones

124 is drug should be first line therapy, unless drug susceptibility testing shows resistance.

125 Compared to phenotypic culture-based drug susceptibility testing, the absence of wild-type pr

126 f isoniazid resistance confirms the need for drug susceptibility testing to guide optimal treatment o

127 r both; MDR or XDR tuberculosis confirmed by drug-susceptibility testing to first-line and second-lin

128 Drug susceptibility test was done using the Kirby-Bauer

129 low cytometric assay for in vitro antifungal drug susceptibility testing was developed by adapting th

130 Molecular drug susceptibility testing was performed on 39 US patie

131 ively known as SIRE), and pyrazinamide (PZA) drug susceptibility testing was performed on 89 clinical

132 Molecular drug susceptibility testing was performed on skin biopsi

133 mmunodeficiency virus (HIV)-infected people, drug susceptibility testing was performed retrospectivel

134 Drug susceptibility testing was performed using the CDC

135 diagnostic workflows, phasing out phenotypic drug-susceptibility testing while reporting drug resista

136 s study demonstrates that the integration of drug susceptibility testing with genotyping and epidemio

137 ng results of isolation, identification, and drug susceptibility testing within 28 days has increased

138 esistant Mycobacterium tuberculosis requires drug susceptibility testing, yet conventional drug susce